Phaseline

Companies › Caravel Oculus

Caravel Oculus: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CA201A (ascorbic acid ophthalmic solution 5%)
Antioxidant; reduces corneal endothelial cell loss through free radical scavenging
–Phase 2Corneal Endothelial Cell LossJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07694375CA201A (ascorbic acid ophthalmic solution 5%)Phase 2Corneal Endothelial Cell LossOphthalmologyJan 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Vantage Biosciences Tourmaline Bio, Inc., a Novartis Company Sunhawk Vision Biotech Qingdao WanMing BioCell Pharmaceutics Tavo Biotherapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.